Literature DB >> 11290500

CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities.

R Avva1, R L Vanhemert, B Barlogie, N Munshi, E J Angtuaco.   

Abstract

BACKGROUND AND
PURPOSE: Cytogenetic abnormalities, especially chromosome 13 deletion, are high-risk factors for multiple myeloma. Attaining the highest detection rates of cytogenetic abnormalities is important to provide accurate prognostic information to the referring oncologist. The purpose of this study was to use CT-guided percutaneous fine-needle aspiration bone biopsy (CT-guided FNA) of MR-detected focal lesions in patients with multiple myeloma to increase identification of abnormal cytogenetics.
METHODS: Patients enrolled in two clinical trials for myeloma therapy underwent MR imaging of the entire spine and pelvis. CT-guided FNA biopsy samples obtained from MR-detected focal lesions in these patients were sent for cytogenetic analysis. FNA results were then compared with random bone marrow sampling of the iliac crest done at or near the same time as the FNA to provide the data revealed in this study.
RESULTS: Forty-one patients (47 lesions) in one of the trials and 37 patients (38 lesions) in the other trial had biopsies performed. CT-guided FNA revealed cytogenetic abnormalities in 21% of the total patient population and new information in nearly 10% of the patients in one trial and in 20% of those in the other trial.
CONCLUSION: CT-guided biopsy of MR-detected focal lesions is a safe technique that can provide important cytogenetic information in a significant number of patients with multiple myeloma not identified during random marrow sampling.

Entities:  

Mesh:

Year:  2001        PMID: 11290500      PMCID: PMC7976013     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  13 in total

1.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

Authors:  R Desikan; B Barlogie; J Sawyer; D Ayers; G Tricot; A Badros; M Zangari; N C Munshi; E Anaissie; D Spoon; D Siegel; S Jagannath; D Vesole; J Epstein; J Shaughnessy; A Fassas; S Lim; P Roberson; J Crowley
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

2.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

Authors:  G Tricot; J R Sawyer; S Jagannath; K R Desikan; D Siegel; S Naucke; S Mattox; D Bracy; N Munshi; B Barlogie
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

Review 3.  Cytogenetics and molecular genetics in multiple myeloma.

Authors:  R Feinman; J Sawyer; J Hardin; G Tricot
Journal:  Hematol Oncol Clin North Am       Date:  1997-02       Impact factor: 3.722

4.  Why better prognostic factors for multiple myeloma are needed.

Authors:  R A Kyle
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

5.  Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.

Authors:  J Drach; J Schuster; H Nowotny; J Angerler; F Rosenthal; M Fiegl; C Rothermundt; A Gsur; U Jäger; R Heinz
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

6.  Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis.

Authors:  B C Van de Berg; F E Lecouvet; L Michaux; M Labaisse; J Malghem; J Jamart; B E Maldague; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1996-10       Impact factor: 11.105

7.  Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.

Authors:  F E Lecouvet; B C Vande Berg; L Michaux; J Malghem; B E Maldague; J Jamart; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1998-12       Impact factor: 11.105

8.  Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.

Authors:  D Tabernero; J F San Miguel; M Garcia-Sanz; L Nájera; M García-Isidoro; J A Peréz-Simon; M Gonzalez; J Wiegant; A K Raap; A Orfão
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

9.  Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease.

Authors:  L A Moulopoulos; D G Varma; M A Dimopoulos; N E Leeds; E E Kim; D A Johnston; R Alexanian; H I Libshitz
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

10.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

View more
  5 in total

1.  Initial CT-guided percutaneous biopsy of vertebral lesions: Evaluation of its diagnostic accuracy and clinical value.

Authors:  Wen-Bin Hua; Qiang Wu; Bo Zhang; Shu-Hua Yang; Zeng-Wu Shao; Wei-Hua Xu; Ye Wang; Xu-Dong Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 2.  Therapy assessment in multiple myeloma with PET.

Authors:  Cristina Nanni; Elena Zamagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-01       Impact factor: 9.236

3.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

4.  Multiple myeloma: a review of imaging features and radiological techniques.

Authors:  C F Healy; J G Murray; S J Eustace; J Madewell; P J O'Gorman; P O'Sullivan
Journal:  Bone Marrow Res       Date:  2011-08-08

Review 5.  Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.

Authors:  Patrizia Tosi
Journal:  Scientifica (Cairo)       Date:  2013-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.